Abstract
Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) is an industry alliance to support research and development projects in AMR. Since its inception in 2016, CARB-X has supported 114 R&D projects across 14 countries, leading to 18 projects advancing into or completing clinical trials. EBM talked to CARB-X Executive Director Kevin Outterson about progress and challenges.
Key Data
-
Publication Date15 April 2025
-
Primary AuthorGeorg Kääb
-
SourceEuropean Biotechnology Magazine
-
LanguageEnglish
Click below to visit original source: